Hearing of the parties – reassessment of reimbursement status for medicinal products for cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09

29 January 2008

Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02, C03, C07, C08 and C09. Reassessment means an assessment of whether there is basis for opening a case on changing the reimbursement status for a medicinal product.

Case no.: 5315-9

The Reimbursement Committee has today sent its recommendation to the Danish Medicines Agency. The recommendation can be found at www.dkma.dk under Companies > General reimbursement > Reassessment of reimbursement status for medicinal products under "Information on reassessment of reimbursement status", where you can also find links to the references on which the Reimbursement Committee has based its recommendation.

As your company <u>as of 13 January 2008</u> has notified the Danish Medicines Agency of a price of one or more medicinal products authorised for marketing in Denmark in one or more of the ATC groups C02, C03, C07, C08 and C09 mentioned above, your medicinal products are comprised by the recommendation made by the Reimbursement Committee.

We should therefore like to call your attention to the Reimbursement Committee's recommendation and the references stated therein and request that you submit any comments on the material by **Monday**, **5 May 2008** at the latest.

The Danish Medicines Agency will include the material and your consultation answer, if any, in its assessment basis when making its decision on the future reimbursement status of the medicinal products in Denmark following the expiry of the consultation deadline.

If you want us to send you a printout of the material, please call us on $+45\,44\,88\,93\,11$.

Yours sincerely,

Elisabeth Thomsen